Health insurance allowance possible for Arimidex as second-line treatment for early breast cancer

Published: 2003-09-17 06:56:00

Updated: 2003-09-17 06:56:00

AstraZeneca Korea said that Arimidex (anastrozole), a typical three-generation adjuvant for the treatment of postmenopausal women with hormone receptor-positive early breast cancer, may be reimbursable following the revised terms for health insurance allowance which took effect on September 9, wh...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK